. Author manuscript; available in PMC: 2017 Feb 28.

Published in final edited form as: Inflamm Bowel Dis. 2014 Apr;20(4):606–613. doi: 10.1097/MIB.0000000000000003

TABLE 3.

Outcomes of Dose Intensification in Patients With UC

At the Time of DI	RRs (n = 4)	NRRs (n = 3)	P
Median (IQR) time to DI after IFX initiation (mo)	11 (9–15)	7 (6–14)	0.42
Median (IQR) CRP (mg/mL)	0.6 (0.4–0.7)	0.5 (0.5–0.6)	0.49
Median (IQR) ESR (mm/h)	21 (16–23)	10 (6–36)	0.38
Median (IQR) Albumin (g/dL)	3.7 (3.7–4.0)	2.6 (2.6–3.5)	0.15
Median (IQR) BSA (m²)	1.4 (1.4–1.5)	1.3 (1.0–1.4)	0.16
Median (IQR) PUCAI	55 (30–55)	35 (25–45)	0.44
ATI detected (%)	0/1 (0)	1/2 (50)	0.39
Median (IQR) duration of IFX (mo)	51 (34–75)	15 (12–18)	0.05

BSA, body surface area; CRP, C-reactive protein; DI, dose intensification; ESR, erythrocyte sedimentation rate; PUCAI, Pediatric Ulcerative Colitis Activity Index.